BR112019006624A2 - método de multiprotease - Google Patents

método de multiprotease

Info

Publication number
BR112019006624A2
BR112019006624A2 BR112019006624A BR112019006624A BR112019006624A2 BR 112019006624 A2 BR112019006624 A2 BR 112019006624A2 BR 112019006624 A BR112019006624 A BR 112019006624A BR 112019006624 A BR112019006624 A BR 112019006624A BR 112019006624 A2 BR112019006624 A2 BR 112019006624A2
Authority
BR
Brazil
Prior art keywords
methods
multiprotease
proteases
protease
protein
Prior art date
Application number
BR112019006624A
Other languages
English (en)
Inventor
Trkulja Carolina
Hägglund Jessica
Davidson Max
Orwar Owe
Original Assignee
Oblique Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oblique Therapeutics Ab filed Critical Oblique Therapeutics Ab
Publication of BR112019006624A2 publication Critical patent/BR112019006624A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

a presente invenção se refere a métodos para identificar um epítopo em uma proteína que pode ser ligada a um anticorpo. os métodos da invenção tipicamente envolvem uma etapa de proteólise limitada ou restrita de uma proteína usando uma primeira protease única ou uma combinação de primeiras proteases, e outra etapa de proteólise usando uma segunda protease única ou combinação de segundas proteases. a invenção também se refere aos epítopos identificados e aos anticorpos os quais se ligam aos epítopos que foram identificados pelos métodos da invenção.
BR112019006624A 2016-10-06 2017-10-06 método de multiprotease BR112019006624A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1617002.9A GB201617002D0 (en) 2016-10-06 2016-10-06 Multi-protease method
PCT/EP2017/075532 WO2018065599A1 (en) 2016-10-06 2017-10-06 Multi-protease method

Publications (1)

Publication Number Publication Date
BR112019006624A2 true BR112019006624A2 (pt) 2019-07-02

Family

ID=57610568

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019006624A BR112019006624A2 (pt) 2016-10-06 2017-10-06 método de multiprotease

Country Status (14)

Country Link
US (1) US11408883B2 (pt)
EP (1) EP3523659A1 (pt)
JP (1) JP7046931B2 (pt)
KR (1) KR102411384B1 (pt)
CN (1) CN109891247B (pt)
AU (1) AU2017339096B2 (pt)
BR (1) BR112019006624A2 (pt)
CA (1) CA3039064A1 (pt)
GB (1) GB201617002D0 (pt)
IL (1) IL265612B2 (pt)
MA (1) MA46454A (pt)
MX (1) MX2019003908A (pt)
NZ (1) NZ752437A (pt)
WO (1) WO2018065599A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41842A (fr) 2015-03-31 2018-02-06 Oblique Therapeutics Ab Nouveaux procédés de sélection d'épitope
GB201918103D0 (en) * 2019-12-10 2020-01-22 Oblique Therapeutics Ab Epitopes and antibodies
CN114853855B (zh) * 2022-04-14 2023-06-20 安徽省华信生物药业股份有限公司 一种具有促降血糖激素glp-1分泌作用的富铬酵母活性肽

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2179036T3 (es) 1990-10-18 2003-01-16 Cancerforskningsfonden Af 1989 .nticuerpos contra el receptor uroquinasa y su uso
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
IL138946A0 (en) * 2000-10-11 2001-11-25 Compugen Ltd Method for the identification of peptides and proteins
WO2003006047A2 (en) 2001-07-13 2003-01-23 Merck Patent Gmbh Methods for reducing immunogenicity of polypeptides
EP2186879B1 (en) * 2002-10-03 2016-11-23 Norman Leigh Anderson High sensitivity quantitation of peptides by mass spectrometry
US7632686B2 (en) * 2002-10-03 2009-12-15 Anderson Forschung Group High sensitivity quantitation of peptides by mass spectrometry
EP2364728A1 (en) 2003-07-15 2011-09-14 Amgen, Inc Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
US20070281986A1 (en) 2004-02-03 2007-12-06 Collier Gregory R Methods and Compositions for Modulating Satiety
WO2006005472A1 (en) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with vanilloid receptor 1 (vr1)
US20060292639A1 (en) 2004-08-13 2006-12-28 Adolor Corporation Splice variant of the vanilloid receptor VR1A
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
SE0403139D0 (sv) 2004-12-23 2004-12-23 Nanoxis Ab Device and use thereof
JP2008175814A (ja) 2006-12-21 2008-07-31 Eisai R & D Management Co Ltd 尿中タンパク質分子の検出・定量による糖尿病性腎症の検査方法及びそれに使用するキット
US20120052592A9 (en) 2007-03-30 2012-03-01 Nano Solution, Inc., Method for determining prognosis of acute central nervous system disorder
US8323651B2 (en) 2008-05-09 2012-12-04 Abbott Laboratories Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
WO2010096385A2 (en) * 2009-02-17 2010-08-26 The Regents Of The University Of Colorado, A Body Corporate, A Colorado Non-Profit Methods and compositions for the treatment of autoimmune disease
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
US9383367B1 (en) 2010-12-07 2016-07-05 Chunli Liu Methods of detecting conjugation site-specific and hidden epitope/antigen
US9476888B2 (en) * 2011-08-08 2016-10-25 Syddansk Universitet Method and antibodies for the identification of ubiquitinated proteins and sites of ubiquitination
MA41842A (fr) * 2015-03-31 2018-02-06 Oblique Therapeutics Ab Nouveaux procédés de sélection d'épitope

Also Published As

Publication number Publication date
IL265612B1 (en) 2023-12-01
NZ752437A (en) 2022-12-23
KR102411384B1 (ko) 2022-06-20
US11408883B2 (en) 2022-08-09
MX2019003908A (es) 2019-06-10
MA46454A (fr) 2019-08-14
RU2019108573A (ru) 2020-11-06
WO2018065599A1 (en) 2018-04-12
EP3523659A1 (en) 2019-08-14
IL265612A (en) 2019-05-30
AU2017339096A1 (en) 2019-05-02
CN109891247B (zh) 2022-10-04
IL265612B2 (en) 2024-04-01
AU2017339096B2 (en) 2023-03-30
JP2020502482A (ja) 2020-01-23
RU2019108573A3 (pt) 2021-01-21
US20200041499A1 (en) 2020-02-06
CN109891247A (zh) 2019-06-14
KR20190062504A (ko) 2019-06-05
GB201617002D0 (en) 2016-11-23
JP7046931B2 (ja) 2022-04-04
CA3039064A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
CL2021000630A1 (es) Métodos para producir un anticuerpo anti-c5 (divisional de la solicitud no. 201701585)
ECSP18095014A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CO2018000886A2 (es) Anticuerpos biespecíficos para pd1 y tim3
CL2019000082A1 (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso.
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
BR112019002579A2 (pt) anticorpos biespecíficos fab monovalentes, assimétricos e tandem
BR112018003326A2 (pt) anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
BR112018070948A2 (pt) anticorpos anti-psma e utilização dos mesmos
BR112018072723A2 (pt) composição, e, métodos para tratar uma doença em um sujeito e para aumentar uma resposta imunológica em um sujeito
BR112018075644A2 (pt) anticorpos anti-cd98 e conjugados de anticorpo e fármaco
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
BR112019006624A2 (pt) método de multiprotease
NZ735823A (en) New methods for epitope selection
CO2017004753A2 (es) Anticuerpos que se unen a ccr6
UY38672A (es) Anticuerpo monoclonal que se une específicamente a gitr
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado
BR112015021964A2 (pt) Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos
CO2023015915A2 (es) Anticuerpos anti-ccr8
BR112019004025A2 (pt) métodos para identificação de epítopos
WO2019025865A3 (en) METHODS AND COMPOSITIONS FOR LIGAND-DIRECTED ANTIBODY DESIGN

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]